These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24694975)

  • 1. [Application progress of macrolide sustained therapy for bronchiectasis].
    Fan L; Xu J
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jan; 37(1):48-50. PubMed ID: 24694975
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials.
    Zhuo GY; He Q; Xiang-Lian L; Ya-Nan Y; Si-Te F
    Pulm Pharmacol Ther; 2014 Oct; 29(1):80-8. PubMed ID: 24594263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Chronic Respiratory Pasteurella multocida Infection Is Well-Controlled by Long-Term Macrolide Therapy.
    Seki M; Sakata T; Toyokawa M; Nishi I; Tomono K
    Intern Med; 2016; 55(3):307-10. PubMed ID: 26831030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of macrolides to diffuse panbronchiolitis].
    Kudoh S
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():554-8. PubMed ID: 17455680
    [No Abstract]   [Full Text] [Related]  

  • 5. A pilot study of low-dose erythromycin in bronchiectasis.
    Tsang KW; Ho PI; Chan KN; Ip MS; Lam WK; Ho CS; Yuen KY; Ooi GC; Amitani R; Tanaka E
    Eur Respir J; 1999 Feb; 13(2):361-4. PubMed ID: 10065682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions.
    Haworth CS; Bilton D; Elborn JS
    Respir Med; 2014 Oct; 108(10):1397-408. PubMed ID: 25301290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations.
    Serisier DJ; Martin ML
    Respir Med; 2011 Jun; 105(6):946-9. PubMed ID: 21367595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathophysiology and treatment of bronchectasis].
    Turcanu AM; Mihăescu T
    Pneumologia; 2011; 60(1):26-9. PubMed ID: 21548197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis.
    Wang D; Fu W; Dai J
    Medicine (Baltimore); 2019 Apr; 98(17):e15285. PubMed ID: 31027086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease.
    Smith D; Du Rand I; Addy CL; Collyns T; Hart SP; Mitchelmore PJ; Rahman NM; Saggu R
    Thorax; 2020 May; 75(5):370-404. PubMed ID: 32303621
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term macrolide treatment for chronic respiratory disease.
    Spagnolo P; Fabbri LM; Bush A
    Eur Respir J; 2013 Jul; 42(1):239-51. PubMed ID: 23180583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment options for bronchiectasis.
    Metersky ML
    Ther Adv Respir Dis; 2010 Apr; 4(2):93-9. PubMed ID: 20388725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The design of novel classes of macrolides for neutrophil-dominated inflammatory diseases.
    Eraković Haber V; Bosnar M; Kragol G
    Future Med Chem; 2014 Apr; 6(6):657-74. PubMed ID: 24895894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evidence base for non-CF bronchiectasis is finally evolving.
    Serisier DJ
    Respirology; 2014 Apr; 19(3):295-7. PubMed ID: 24620757
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of macrolides in lung diseases: recent literature controversies.
    Silva Filho LV; Pinto LA; Stein RT
    J Pediatr (Rio J); 2015; 91(6 Suppl 1):S52-60. PubMed ID: 26354869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: A systematic review and adjusted indirect treatment comparison.
    Li W; Qin Z; Gao J; Jiang Z; Chai Y; Guan L; Chen Y
    Chron Respir Dis; 2019; 16():1479972318790269. PubMed ID: 30101613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review.
    Shi ZL; Peng H; Hu XW; Hu JG
    Pulm Pharmacol Ther; 2014 Aug; 28(2):171-8. PubMed ID: 24076368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalation of macrolides: a novel approach to treatment of pulmonary infections.
    Siekmeier R; Hofmann T; Scheuch G
    Adv Exp Med Biol; 2015; 839():13-24. PubMed ID: 25252902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
    Amsden GW
    J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.
    Wu Q; Shen W; Cheng H; Zhou X
    Respirology; 2014 Apr; 19(3):321-9. PubMed ID: 24417869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.